QUOTE AND NEWS
Marketwire  Jun 17  Comment 
SAN DIEGO, CA -- (Marketwire) -- 06/17/10 -- Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today the appointment of industry veteran Thomas Zech as Chief
Marketwire  Jun 3  Comment 
SYDNEY, AUSTRALIA and SAN DIEGO, CA -- (Marketwire) -- 06/03/10 -- Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today that Daniel P. Gold, Ph.D., newly
Marketwire  Jun 1  Comment 
SYDNEY, AUSTRALIA and SAN DIEGO, CA -- (Marketwire) -- 06/01/10 -- Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today that a final analysis of its Phase 3
Marketwire  May 24  Comment 
NEW CANAAN, CT -- (Marketwire) -- 05/24/10 -- Marshall Edwards, Inc. (NASDAQ: MSHL), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics, announced today that on May 18, 2010 it received a notice from
Marketwire  May 21  Comment 
SAN DIEGO, CA -- (Marketwire) -- 05/21/10 -- Marshall Edwards, Inc., (NASDAQ: MSHL). An abstract titled "A phase II study of oral phenoxodiol in castrate and non-castrate prostate cancer patients with associated cytokine changes" by Dr Kevin Kelly at
Marketwire  May 6  Comment 
SYDNEY, AUSTRALIA and SAN DIEGO, CA -- (Marketwire) -- 05/06/10 -- Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced that Daniel Gold, Ph.D., the Company's
Marketwire  Apr 29  Comment 
SYDNEY, AUSTRALIA and SAN DIEGO, CA -- (Marketwire) -- 04/29/10 -- Marshall Edwards, Inc. (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics, announced today the approval of
Marketwire  Apr 26  Comment 
SYDNEY, AUSTRALIA and SAN DIEGO, CA -- (Marketwire) -- 04/26/10 -- Marshall Edwards, Inc. (NASDAQ: MSHLD), an oncology company focused on the clinical development of novel anti-cancer therapeutics, is pleased to announce that Daniel Gold, Ph.D., an
Marketwire  Apr 20  Comment 
NEW CANAAN, CT -- (Marketwire) -- 04/20/10 -- Marshall Edwards, Inc. (NASDAQ: MSHL), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics, today announced that the Company has received notice from the
Marketwire  Mar 31  Comment 
NEW CANAAN, CT -- (Marketwire) -- 03/31/10 -- Marshall Edwards, Inc. (NASDAQ: MSHL) (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics, today announced that a Special Meeting of





 



References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki